• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超级增强子驱动的 LIF/LIFR-STAT3-SOX2 调控反馈回路促进头颈部鳞状细胞癌的癌症干性。

Super-Enhancer Driven LIF/LIFR-STAT3-SOX2 Regulatory Feedback Loop Promotes Cancer Stemness in Head and Neck Squamous Cell Carcinoma.

机构信息

Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital of Nanjing Medical University, Jiangsu, 210029, China.

Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University, Jiangsu, 210029, China.

出版信息

Adv Sci (Weinh). 2024 Oct;11(40):e2404476. doi: 10.1002/advs.202404476. Epub 2024 Aug 29.

DOI:10.1002/advs.202404476
PMID:39206755
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11516160/
Abstract

Super-enhancers (SEs) have been recognized as key epigenetic regulators underlying cancer stemness and malignant traits by aberrant transcriptional control and promising therapeutic targets against human cancers. However, the SE landscape and their roles during head and neck squamous cell carcinoma (HNSCC) development especially in cancer stem cells (CSCs) maintenance remain underexplored yet. Here, we identify leukemia inhibitory factor (LIF)-SE as a representative oncogenic SE to activate LIF transcription in HNSCC. LIF secreted from cancer cells and cancer-associated fibroblasts promotes cancer stemness by driving SOX2 transcription in an autocrine/paracrine manner, respectively. Mechanistically, enhancer elements E1, 2, 4 within LIF-SE recruit SOX2/SMAD3/BRD4/EP300 to facilitate LIF transcription; LIF activates downstream LIFR-STAT3 signaling to drive SOX2 transcription, thus forming a previously unknown regulatory feedback loop (LIF-SE-LIF/LIFR-STAT3-SOX2) to maintain LIF overexpression and CSCs stemness. Clinically, increased LIF abundance in clinical samples correlate with malignant clinicopathological features and patient prognosis; higher LIF concentrations in presurgical plasma dramatically diminish following cancer eradication. Therapeutically, pharmacological targeting LIF-SE-LIF/LIFR-STAT3 significantly impairs tumor growth and reduces CSC subpopulations in xenograft and PDX models. Our findings reveal a hitherto uncharacterized LIF-SE-mediated auto-regulatory loop in regulating HNSCC stemness and highlight LIF as a novel noninvasive biomarker and potential therapeutic target for HNSCC.

摘要

超级增强子(SEs)已被认为是通过异常转录控制和有前途的人类癌症治疗靶点来支持癌症干性和恶性特征的关键表观遗传调节剂。然而,SE 景观及其在头颈部鳞状细胞癌(HNSCC)发展中的作用,尤其是在癌症干细胞(CSCs)维持方面,仍未得到充分探索。在这里,我们确定白血病抑制因子(LIF)-SE 作为一种代表性的致癌 SE,可激活 HNSCC 中的 LIF 转录。癌细胞和癌症相关成纤维细胞分泌的 LIF 通过自分泌/旁分泌方式分别驱动 SOX2 转录,从而促进癌症干性。在机制上,LIF-SE 内的增强子元件 E1、2、4 招募 SOX2/SMAD3/BRD4/EP300 以促进 LIF 转录;LIF 激活下游的 LIFR-STAT3 信号通路,驱动 SOX2 转录,从而形成一个以前未知的调节反馈环(LIF-SE-LIF/LIFR-STAT3-SOX2),以维持 LIF 的过表达和 CSCs 的干性。临床上,临床样本中 LIF 的丰度增加与恶性临床病理特征和患者预后相关;癌症消除后,术前血浆中的 LIF 浓度显著降低。在治疗上,药物靶向 LIF-SE-LIF/LIFR-STAT3 可显著抑制肿瘤生长,并减少异种移植和 PDX 模型中的 CSC 亚群。我们的研究结果揭示了一个以前未被描述的 LIF-SE 介导的自我调节环,用于调节 HNSCC 干性,并强调 LIF 作为一种新的非侵入性生物标志物和潜在的 HNSCC 治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/fe6648117733/ADVS-11-2404476-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/d0e85c67a58f/ADVS-11-2404476-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/057a3a9f7002/ADVS-11-2404476-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/0ec2bb1c4159/ADVS-11-2404476-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/e640f1dac258/ADVS-11-2404476-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/fa24d89b54f3/ADVS-11-2404476-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/491bfa15c608/ADVS-11-2404476-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/012219ade0df/ADVS-11-2404476-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/fe6648117733/ADVS-11-2404476-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/d0e85c67a58f/ADVS-11-2404476-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/057a3a9f7002/ADVS-11-2404476-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/0ec2bb1c4159/ADVS-11-2404476-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/e640f1dac258/ADVS-11-2404476-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/fa24d89b54f3/ADVS-11-2404476-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/491bfa15c608/ADVS-11-2404476-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/012219ade0df/ADVS-11-2404476-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/736a/11516160/fe6648117733/ADVS-11-2404476-g005.jpg

相似文献

1
Super-Enhancer Driven LIF/LIFR-STAT3-SOX2 Regulatory Feedback Loop Promotes Cancer Stemness in Head and Neck Squamous Cell Carcinoma.超级增强子驱动的 LIF/LIFR-STAT3-SOX2 调控反馈回路促进头颈部鳞状细胞癌的癌症干性。
Adv Sci (Weinh). 2024 Oct;11(40):e2404476. doi: 10.1002/advs.202404476. Epub 2024 Aug 29.
2
The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma.Hippo 效应物 TAZ 通过转录激活头颈部鳞状细胞癌中的 SOX2 促进癌症干性。
Cell Death Dis. 2019 Aug 9;10(8):603. doi: 10.1038/s41419-019-1838-0.
3
Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells.肿瘤细胞 CD44 介导巨噬细胞/单核细胞对头颈部癌症干细胞的调控作用。
Cancer Res. 2020 Oct 1;80(19):4185-4198. doi: 10.1158/0008-5472.CAN-20-1079. Epub 2020 Aug 14.
4
Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.阻断去泛素化酶 PSMD14 通过拮抗 E2F1/Akt/SOX2 介导的干性克服头颈部鳞状细胞癌的化疗耐药性。
Theranostics. 2021 Jan 1;11(6):2655-2669. doi: 10.7150/thno.48375. eCollection 2021.
5
Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness.应激触发的 YAP1/SOX2 激活转录重编程头颈部鳞状细胞癌以获得干性。
J Cancer Res Clin Oncol. 2019 Oct;145(10):2433-2444. doi: 10.1007/s00432-019-02995-z. Epub 2019 Sep 4.
6
Autophagy regulates the cancer stem cell phenotype of head and neck squamous cell carcinoma through the noncanonical FOXO3/SOX2 axis.自噬通过非经典FOXO3/SOX2轴调节头颈部鳞状细胞癌的癌症干细胞表型。
Oncogene. 2022 Jan;41(5):634-646. doi: 10.1038/s41388-021-02115-7. Epub 2021 Nov 19.
7
AFF4 promotes tumorigenesis and tumor-initiation capacity of head and neck squamous cell carcinoma cells by regulating SOX2.AFF4 通过调控 SOX2 促进头颈部鳞状细胞癌细胞的致瘤性和肿瘤起始能力。
Carcinogenesis. 2018 Jul 3;39(7):937-947. doi: 10.1093/carcin/bgy046.
8
Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma.转录超级增强子控制鳞状细胞癌中的癌症干细胞和转移基因。
Nat Commun. 2021 Jun 25;12(1):3974. doi: 10.1038/s41467-021-24137-1.
9
Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma.表观遗传学分析鉴定 LIF 为骨肉瘤中干细胞样特性的超级增强子控制调节剂。
Mol Cancer Res. 2020 Jan;18(1):57-67. doi: 10.1158/1541-7786.MCR-19-0470. Epub 2019 Oct 15.
10
FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program.FOSL1 通过超级增强子驱动的转录程序促进头颈部鳞状细胞癌的转移。
Mol Ther. 2021 Aug 4;29(8):2583-2600. doi: 10.1016/j.ymthe.2021.03.024. Epub 2021 Mar 29.

引用本文的文献

1
Role of exosomal non‑coding RNAs in cancer‑associated fibroblast‑mediated therapy resistance (Review).外泌体非编码RNA在癌症相关成纤维细胞介导的治疗耐药中的作用(综述)
Int J Oncol. 2025 Aug;67(2). doi: 10.3892/ijo.2025.5774. Epub 2025 Jul 19.
2
Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications.靶向肝癌中的超级增强子:从致病机制到临床应用
Front Pharmacol. 2025 Jun 18;16:1589455. doi: 10.3389/fphar.2025.1589455. eCollection 2025.
3
DUSP3 restrains the progression and stemness property of osteosarcoma through regulating EGFR/STAT3/SOX2 axis.

本文引用的文献

1
TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer.TWEAK/Fn14 信号驱动的超级增强子重编程促进三阴性乳腺癌的促转移代谢重排。
Nat Commun. 2024 Jul 5;15(1):5638. doi: 10.1038/s41467-024-50071-z.
2
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
3
CYTOR Facilitates Formation of FOSL1 Phase Separation and Super Enhancers to Drive Metastasis of Tumor Budding Cells in Head and Neck Squamous Cell Carcinoma.
双特异性磷酸酶3通过调控表皮生长因子受体/信号转导和转录激活因子3/性别决定区Y框蛋白2轴抑制骨肉瘤的进展和干性特性。
Int J Biol Sci. 2025 Jan 1;21(1):160-174. doi: 10.7150/ijbs.101137. eCollection 2025.
细胞因子诱导的环状RNA(CYTOR)促进FOSL1相分离和超级增强子的形成,以驱动头颈部鳞状细胞癌中肿瘤芽生细胞的转移。
Adv Sci (Weinh). 2024 Jan;11(4):e2305002. doi: 10.1002/advs.202305002. Epub 2023 Nov 30.
4
RGT: a toolbox for the integrative analysis of high throughput regulatory genomics data.RGT:一个用于高通量调控基因组学数据综合分析的工具包。
BMC Bioinformatics. 2023 Mar 6;24(1):79. doi: 10.1186/s12859-023-05184-5.
5
Leukemia inhibitory factor, a double-edged sword with therapeutic implications in human diseases.白血病抑制因子,人类疾病治疗中具有双刃剑效应的分子。
Mol Ther. 2023 Feb 1;31(2):331-343. doi: 10.1016/j.ymthe.2022.12.016. Epub 2022 Dec 26.
6
A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma.局部肿瘤微环境获得超级增强子诱导结直肠癌中的致癌驱动因子。
Nat Commun. 2022 Oct 17;13(1):6041. doi: 10.1038/s41467-022-33377-8.
7
Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy.头颈鳞状细胞癌的药物基因组学全景分析为精准肿瘤学治疗提供信息。
Sci Transl Med. 2022 Sep 7;14(661):eabo5987. doi: 10.1126/scitranslmed.abo5987.
8
The deubiquitinase USP7 promotes HNSCC progression via deubiquitinating and stabilizing TAZ.去泛素化酶 USP7 通过去泛素化和稳定 TAZ 促进 HNSCC 进展。
Cell Death Dis. 2022 Aug 5;13(8):677. doi: 10.1038/s41419-022-05113-z.
9
High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma.高增强子活性是HPV阴性非典型头颈部鳞状细胞癌的一种表观遗传特征。
Front Cell Dev Biol. 2022 Jul 19;10:936168. doi: 10.3389/fcell.2022.936168. eCollection 2022.
10
A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer.多组学剖析卵巢癌中超增强子驱动的致癌基因表达程序。
Nat Commun. 2022 Jul 22;13(1):4247. doi: 10.1038/s41467-022-31919-8.